Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada (GRACE)

AbbVie

Status: Completed

Conditions: Endometriosis

Study type: Observational

Funder types: Industry

Identifiers

NCT04080856

P19-933

Details and patient eligibility

About

The objective of this study is to evaluate real-world effectiveness of elagolix in Canadian women with endometriosis.

Enrollment: 100 patients

Sex: Female

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prescribed elagolix as part of standard treatment
• Naive to elagolix prior to starting this study or have stopped taking elagolix for 2 months prior to the start of this study
• Symptomatic endometriosis (clinically or surgically diagnosed) including currently experiencing dysmenorrhea
• Has provided written informed consent allowing the use of their data for the study

Exclusion criteria

• Did not consent
• Cannot fill out questionnaires
• Prescribed elagolix for a period of 1 or 2 months only
• Post-menopausal (naturally or surgically)
• Symptomatic uterine fibroid(s)
• Had medical treatment for uterine fibroids (any length of treatment)

Trial design

100 participants in 1 patient group

Participants with endometriosis

Description:

Premenopausal participants with endometriosis receiving elagolix in real-world setting